Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
IN8BIO, INC. (INAB) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/12/2023 8-K Quarterly results
08/10/2023 8-K Quarterly results
Docs: "IN8bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update • Presented positive INB-200 Phase 1 data in an oral presentation at the American Society of Clinical Oncology Annual Meeting showing 100% of treated patients have exceeded historical median progression-free survival • INB-400 on track to initiate enrollment in glioblastoma multiforme in the second half of 2023. The Phase 2 trial will initially enroll newly diagnosed GBM patients in the autologous setting. The primary endpoint of the study is overall survival ; secondary endpoints include tolerability, progression-free survival , overall response rate and time to progression • Promising preclinical data in ovarian cancer announced at the American Society of Gene & Cell Therapy Annual Mee..."
06/16/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
05/17/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"IN8bio's DeltEx Gamma-Delta T Cells Show Promise in Targeting Ovarian Cancer"
05/12/2023 8-K Quarterly results
Docs: "IN8bio Reports First Quarter 2023 Financial Results and Provides Corporate Update • Presented positive INB-100 data showing long-term complete remissions and elevated gamma-delta T cell levels in 100% of evaluable treated leukemia patients; Dose Level 2 selected as the recommended Phase 2 dose for the ongoing expansion with clinical updates expected in late 2023. • Progress across preclinical programs, including data demonstrating that gamma-delta T cells have the ability to target other solid tumors, including ovarian cancer, expanding the scope of their potential application beyond brain tumors, as well as encouraging preclinical data in the new INB-330 CAR-T program targeting acute myeloid leukemia . • Obtained FDA orphan drug designation for INB-400 and INB-410, wh..."
05/01/2023 8-K Quarterly results
04/24/2023 8-K Quarterly results
04/17/2023 8-K Quarterly results
02/23/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "IN8bio Presents Preclinical Data Showing Non-Signaling CAR Platform Targets Cancer Cells While Preserving Healthy Tissue"
01/05/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"IN8bio Provides INB-200 Clinical Update and Outlines 2023 Pipeline Goals"
12/08/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"IN8bio Announces FDA Clearance to Initiate a Phase 2 Clinical Trial of INB-400 Gamma-Delta T Cells for Glioblastoma"
10/13/2022 8-K Regulation FD Disclosure  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
08/19/2022 8-K Quarterly results
08/16/2022 8-K Quarterly results
08/12/2022 8-K Quarterly results
08/08/2022 8-K Results of Operations and Financial Condition  Interactive Data
07/27/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "IN8bio Observes Durable Morphologic Complete Responses in Ongoing Phase 1 Clinical Trial of INB-100, an Allogeneic Gamma-Delta T Cell Therapy in High-Risk Leukemia Patients"
06/08/2022 8-K Quarterly results
06/02/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
03/28/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "FORM 8-K",
"IN8bio Presents Clinical Update from the Ongoing Phase 1 Trial of INB-100, an Allogeneic Gamma-Delta T Cell Therapy in Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant"
03/17/2022 8-K Quarterly results
01/10/2022 8-K Regulation FD Disclosure  Interactive Data
12/16/2021 8-K Quarterly results
12/09/2021 8-K Quarterly results
11/10/2021 8-K Quarterly results
Docs: "IN8bio Reports Third Quarter 2021 Financial Results and Provides Corporate Update"
09/10/2021 8-K Quarterly results
08/03/2021 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
Docs: "Amended and Restated Certificate of Incorporation of the Registrant",
"Amended and Restated Bylaws of the Registrant"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy